You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.
Alzheimer's Association 24/7 Helpline800-272-390024 hours a day, 365 days a yearFree, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
988 Suicide & Crisis Lifeline98824/7Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
Alzheimer's Foundation of America (AFA) Helpline866-232-84849:00 am - 9:00 pm ET, seven days a weekLicensed social workers providing support, info and referrals. Also text message and web chat.Text: 646-586-5283
In a medical emergency, call 911.
More numbers, and what each line does, on the help page.
Research
30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.
Find studies
Showing 2,676–2,700 of 2,931 studies published 2025 · free to read(page 108 of 118)· 30,980 in the whole library·How the 0–100 score works
Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)
From OpenAlex; 16,452 studies have no institution on record and are not counted here.
A note on reading research. One study is rarely the final word.
We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.
These inputs and activities were shown in the logic model to result in short, medium, and long-term outcomes, including reduced healthcare resource use and increased quality of life for people with dementia at the end of life. 2 key findings →
Our case series highlighted the relevance of neurological comorbidities in BP patients; although the pathogenesis is still to be elucidated, the neuroinflammation present in neurodegenerative diseases could explain the neurocutaneous link and the chronological relationship between these entities. 3 key findings →
✓ Peer-reviewedalzhub usefulness score 32 out of 100.·Innovation in Aging·2025-12-01
Persons with dementia were significantly more likely to enter HHC directly from the community (60% vs. 37%, adjusted OR = 1.52, 95% CI = 1.50-1.53). 2 key findings →
The Dementia Datahub (https://dementiadatahub.org/) currently provides mapping, data reporting dashboards, system documentation, and public use files (available upon request) of statistics from the year 2020. 5 key findings →
✓ Peer-reviewedalzhub usefulness score 32 out of 100.·Innovation in Aging·2025-12-01
Successfully embedding technology into long-term care settings requires intentional, evidence-based community engagement strategies that address the unique needs of providers, caregivers, and persons living with dementia. 1 key finding →
Higher densities of civic organizations were associated with lower county dementia incidence, while museums and recreational facilities were associated with lower prevalence and incidence. 5 key findings →
✓ Peer-reviewedalzhub usefulness score 32 out of 100.·SLEEP Advances·2025-01-01
Idiopathic rapid eye movement (REM) sleep behavior disorder (iRBD) is characterized by the loss of atonia during REM sleep, causing dream-enacting behavior. 4 key findings →
✓ Peer-reviewedalzhub usefulness score 32 out of 100.·Innovation in Aging·2025-12-01
Overall, our findings suggest that greater neighborhood disadvantage may influence select domains of memory, and that one’s self-reported loneliness may influence how this relationship manifests. 4 key findings →
✓ Peer-reviewedalzhub usefulness score 32 out of 100.·Innovation in Aging·2025-12-01
Specifically, higher inflammation was associated with worse processing speed (B = -0.01; p < .05) and working memory (B = 8323.66; p < .1) only among those from more disadvantaged neighborhoods. 3 key findings →
To the Editor: We have recently highlighted the potential pitfalls of amyloid-beta (Aβ) PET, suggesting that both Aβ and tau assessments are necessary to relate clinical symptoms to Alzheimer disease (AD) pathology.1 Herein, we would like to present 3 additional cases related to the clinical practice of disease-modifying therapy (DMT) for AD. 4 key findings →
The MoCA shows superior sensitivity for MCI detection compared to the Mini-Mental State Examination (MMSE), with strengths in brevity, multidomain coverage, and accessibility. 5 key findings →
✓ Peer-reviewedalzhub usefulness score 32 out of 100.·JMIR Aging·2025-11-14
This ultra-brief questionnaire enables rapid screening for cognitive impairment (in <1 min) by family members or as part of community geriatric assessments. 2 key findings →
Respite goal achievement on a given week predicted improvements in participants' ratings of their respite time-use outcomes one week later. 5 key findings →
✓ Peer-reviewedalzhub usefulness score 32 out of 100.·SSM - Mental Health·2025-06-24
Caregiving interventions can reduce caregiver burden and promote caregiver competence, yet caregiving is rooted in culture, with differing impacts of the caregiving role. 5 key findings →
✓ Peer-reviewedalzhub usefulness score 32 out of 100.·BMC Family Practice·2025-09-16
The analysis revealed six main themes: 'Core health care challenges,' 'communication approaches and information sharing,' 'role of GP,' 'situation of caregivers,' 'influence on caregiver-GP relationship,' and 'socio-cultural barriers and care preferences'. 5 key findings →
Free full text links and the Full text may need a subscription
label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor,
and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a
scientist can tell a landmark trial from a conference abstract without having to already know the
difference. Every point comes from one of 20 components, all of them printed on the study itself,
so you can disagree with our arithmetic rather than having to trust the total.
Journal tierup to 10 pts
Journal's citation recordup to 4 pts
Study designup to 12 pts
Strength of evidenceup to 5 pts
Peer-review validationup to 10 pts
How recentup to 5 pts
Sample sizeup to 4 pts
Effect reportedup to 3 pts
Studied in peopleup to 3 pts
Randomised / blindedup to 2 pts
Times citedup to 7 pts
Citations per yearup to 5 pts
Impact for its field and yearup to 6 pts
Cited by studies hereup to 6 pts
Still being citedup to 4 pts
Senior author's track recordup to 4 pts
Institution's track recordup to 3 pts
Multi-centre collaborationup to 3 pts
Indexed in PubMedup to 2 pts
Free to readup to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we
could not verify current impact factors from a source we control, and an invented one would be
worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science,
Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed
journal. A separate part scores how much the journal's own papers are cited, which tells the
tier-3 journals apart.
Two rules we don't bend. First, we never fill in a
missing value: if a record does not state a sample size or a design, that component scores
zero, and if we simply have no data for a part, such as a citation count, that part is left out and
the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed
article is capped at 16/100 and carries a warning chip — so a conference abstract or
a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not
work — above an early positive finding. Someone deciding whether to buy a supplement is served by
that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is
reproducible: the same file always yields the same numbers.
See the whole rubric drawn out →
— four charts covering all 30,980 studies: how the scores are spread and where the cap
bites, which of the 20 components the library is strong and weak on, which subjects rest on
stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of
it. It holds 30,980 records, built mostly from automated pulls of Europe PMC
(65.2% of the library) and OpenAlex (16.4%),
plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here,
that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,040 records (3.4% of the
library) are not peer-reviewed — 965 of those are preprints posted before any
journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card
on this page states its status plainly, and the score above is capped for anything that isn't a
peer-reviewed article.